

X<sub>2</sub> is a -CH<sub>2</sub>OCH<sub>2</sub>-, -CH<sub>2</sub>SCH<sub>2</sub>- or alkylene group;  
X<sub>3</sub> is an oxygen or sulphur atom;  
A<sub>3</sub> is an aryl or heteroaryl <sup>group</sup> and  
A<sub>4</sub> is hydrogen, (C<sub>1-6</sub>)alkyl, (C<sub>3-8</sub>)cycloalkyl,  
(C<sub>3-8</sub>)cycloalkyl(C<sub>1-6</sub>)alkyl, (C<sub>1-6</sub>)alkoxycarbonyl(C<sub>1-6</sub>)alkyl,  
(C<sub>2-6</sub>)alkenyl, carboxy(C<sub>1-6</sub>)alkyl, (C<sub>2-6</sub>)alkynyl, aryl or  
(C<sub>1-6</sub>)alkyl substituted by up to three aryl groups.

R E M A R K S

Pursuant to the Examiner's request, a substitute specification of the present application on one-side of the paper, is enclosed herewith.

The specification is objected to under 35 U.S.C. § 112, first paragraph, for failing to enable disclosure. The Examiner's rejection is based on the recitation of "heteroaromatic" in claim 57 on lines 5 to 10 of page 3 and "heterocycl" on line 8 of page 2. Claim 57 has been amended to delete "heteroaromatic" and "heterocycl" from the noted lines, thereby obviating the Examiner's rejection.

Claims 57-68 are rejected under 35 U.S.C. § 112, first paragraph, for the same reasons set forth in the objection to the specification. The instant amendment to claim 57 obviates the Examiner's rejection for the reasons set forth above with respect to the Examiner's objection to the specification.

Claim 68 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicant submits that

146

the term "therapeutically" clarifies and defines "effective amount" in that the effective amount is that amount which provides for a therapeutic effect in the treatment of bacterial infections. The term "therapeutically" distinctly claims the invention because it is clear from the specification (page 1 lines 1-6) that the disease(s) associated with the recitation "therapeutically "effective amount" encompasses various bacterial infections in humans and animals caused by a wide range of organisms. See for example, page 29 lines 20 to 27 of the specification, where it is noted that the compositions of the present invention are useful for the treatment of bacterial infection in mammals including humans. Furthermore, the Examples of the specification describe the activity of various compounds covered by the method of claim 68 against various bacteria, including E. coli and S. aureus (specification page 34 lines 29 to 35). Thus Applicant has provided a general description of the usefulness or therapeutic value of the compounds recited in the method of claim 68, as well as specific compounds covered by claim 68 which exhibit activity against particular bacterial infections. Applicant therefore respectfully submits the rejection of claim 68 under 35 U.S.C. § 112 be withdrawn.

C

In view of the above amendment and remarks, favorable consideration and allowance of claims 57-68 is earnestly solicited.

Respectfully submitted,

Dated: January 16, 1997


Pfizer Inc.

Patent Dept., 20th Floor

235 East 42nd Street

New York, NY 10017-5755

(212) 573-2030



Lorraine B. Ling

Attorney for Applicants

Reg. No. 35,251